Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial
JAMA Oncol
.
2023 Feb 1;9(2):275-276.
doi: 10.1001/jamaoncol.2022.6138.
Authors
William A Hall
1
2
,
Douglas B Evans
2
,
Susan Tsai
2
Affiliations
1
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.
2
Department of Surgical Oncology, Medical College of Wisconsin, Milwaukee.
PMID:
36454556
DOI:
10.1001/jamaoncol.2022.6138
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Fluorouracil / therapeutic use
Humans
Neoadjuvant Therapy*
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / radiotherapy
Substances
Fluorouracil